Redeye: Alligator Bioscience Q3 2024 - Approaching the Decisive Moment
Redeye comments on Alligator's Q3 report. The main event since our last update was the ALG.APV-527 phase I readout. Considering the limited runway and intention to begin a phase III study by mid-2025, Alligator will have to sign a deal in the very near future.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/